Rilotumumab (** Investigational drug (no approved brand names - development discontinued) **)
Immunotherapy
Description
Rilotumumab was investigated for its potential to inhibit tumor growth and progression in colorectal cancer by targeting PDGFRA. It has been studied primarily as a single agent or in combination with chemotherapy, but development was discontinued due to lack of efficacy compared to standard treatments.
Mechanism of Action
Rilotumumab is a recombinant humanized monoclonal antibody that binds to and inhibits the function of platelet-derived growth factor receptor alpha (PDGFRA), which is involved in angiogenesis and tumor cell proliferation.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | ** Investigational drug (no approved brand names - development discontinued) ** |
| Category | Immunotherapy |
 EMA Status | Not submitted to EMA |
 Spain Access | Not available |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.